BRAIN.Q
Restorative Brain Health Therapeutics to Reverse Disability After Neurological Disease
Company Overview
Snapshot
Founded in August 2016 by Yotam Drechsler, Prof. Esther Shohami, and Yaron Segal, BRAIN.Q operates with 11–50 employees. The company has raised a total of $52.4M across 4 funding rounds from 11 investors. In August 2021, BRAIN.Q secured a funding round led by Hanaco Ventures and OurCrowd.
Business overview
BRAIN.Q is a Health Tech & Life Sciences company focused on redefining neurological recovery through innovative, non-invasive therapies. The company leverages advanced AI-powered technology to develop network-targeting electromagnetic precision therapy, specifically designed to enhance and accelerate brain recovery following ischemic stroke. Its cloud-based platform delivers the therapy, making it adaptable for both hospital and home settings. BRAIN.Q operates within the Digital Healthcare and Digital Therapeutics sectors, serving global markets including North America, India, Israel, and Europe, targeting patients and providers.
Strategic signal
In June 2024, BRAIN.Q was recognized as a Tech Pioneer by the World Economic Forum for its innovative brain health platform aimed at treating stroke disability. This recognition highlights the company's leadership in neurological innovation and validates its approach to leveraging AI-powered electromagnetic therapy to address a significant global health challenge, signaling strong potential for future market adoption and strategic partnerships.
Log in to access full profile ›Company Intelligence Q&A
- What is BRAIN.Q's core mission?
- BRAIN.Q's mission is to transform lives through innovative, noninvasive therapies for neurological recovery, aiming to restore brain health and dignity to stroke survivors.
- What significant regulatory milestones has BRAIN.Q achieved?
- BRAIN.Q has earned CE Mark approval and the FDA’s Breakthrough Device Designation for its technology.
- When did BRAIN.Q enroll its first patient in the pivotal EMAGINE trial?
- In December 2021, BRAIN.Q enrolled the first patient in its pivotal EMAGINE trial for frequency-tuned electromagnetic field therapy to reduce disability following ischemic stroke.
- What was a key development for BRAIN.Q in August 2021?
- In August 2021, BRAIN.Q raised a funding round led by Hanaco Ventures and OurCrowd to advance its home therapy device for stroke patient rehabilitation.
- What recognition did BRAIN.Q receive in June 2024?
- In June 2024, BRAIN.Q was recognized as a Tech Pioneer by the World Economic Forum for its innovative brain health platform designed to treat stroke disability.